Plexera Bioscience Ships First Plexera(TM) K(X)5 Analyzer to Early Access Partner
Lumera zu myNews hinzufügen Was ist das?
Plexera Bioscience LLC, a wholly owned subsidiary of Lumera Corporation
(NASDAQ:LMRA), announced today that it has shipped a pre-commercial
version of its novel Plexera™ KX5
Analyzer. Plexera’s first Early Access Partner
is a pharmaceutical company who will be evaluating the system as a tool
for screening and characterizing antibody libraries. As part of the
early access agreement, the customer will have a 90 day period following
installation to evaluate the platform. Pending positive evaluation
results, the customer has agreed to purchase a commercial version of the KX5
Analyzer. A second early access partner is anticipated in the second
quarter.
As previously announced, Plexera intends to formally launch the Plexera™ KX5 System at the Protein
Engineering Summit (PEGS) in early May. As part of the Early Access
Program, partners will provide application and performance data to be
used in conjunction with the launch.
"Shipment of this instrument is a key
milestone in our development path,” said Dr.
Timothy Londergan, President and Chief Operating Officer of Plexera. "There
are number of key innovations which bring about significant advancements
in both usability and performance and we are excited to get these in
front of the customer.”
The KX5 Analyzer is a core
component of the Plexera™ KX5
System, which provides multiplexed, label-free, kinetic analysis of
thousands of biomolecular interactions in single experiment. The Plexera™ KX5 System is a fully
integrated platform that also includes array printing, sensor chips with
specialized surface chemistries, and sophisticated data analysis
software. Numerous innovations including a revolutionary new fluidic
design which includes a novel pump and valve system and a microfluidic
cell designed for low sample consumption have been integrated into the
Plexera™ KX5
Analyzer. Patent applications for these innovations have been submitted.
A summary of 2007 Goals and Objectives are as follows:
Academic Beta Site Publications: A joint publication between the
Institute for Systems Biology (ISB) and the University of Washington was
submitted in November while a second manuscript from Medical University
of South Carolina is targeted for a late January submission.
Additionally, a paper co-authored by a Plexera scientist and a
University of Washington scientist was published in 2007 in the Journal Biomaterials.
An additional publication from ISB is expected to be submitted in the
first quarter of 2008.
ISO 9001-2000 Compliant: In 2007, Plexera succeeded in
implementing a Quality Management System (QMS), a necessary precursor to
ISO certification. Several significant milestones have been met towards
certification. In the fourth quarter, Plexera successfully completed a
pre-assessment audit. Following successful completion of the
certification audit scheduled to take place by the end of the first
quarter of 2008, Plexera anticipates being fully ISO 9001-2000 compliant.
Co-marketing arrangement with Printer Partners: After extensive
market and technical evaluations of commercially available microarray
printers, two commercial printers have been selected that will become
validated instrument components of the KX5
instrument system. Plexera will market the KX5
Analyzer along with the printers as an integrated instrument system
to biomarker and antibody discovery customers.
Array Manufacturing Partner qualified and established: Three
potential array manufacturing partners have been selected from a group
totaling eight. Final beta sampling will culminate in the first quarter
of 2008 establishing a primary and secondary source.
About Plexera Biosciences LLC
Plexera Biosciences LLC., a wholly owned subsidiary of Lumera
Corporation (NASDAQ:LMRA), is focused on providing the life sciences
market with tools, content, and methods that simply and accelerate
proteomic discovery for improved diagnostics and therapeutics. For more
information, please visit www.plexera.com.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties. Factors
that could cause actual results to differ materially from those
projected in the company's forward-looking statements include the
following: market acceptance of our technologies and products; our
ability to obtain financing; our financial and technical resources
relative to those of our competitors; our ability to keep up with rapid
technological change; government regulation of our technologies; our
ability to enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from time
to time in the company's SEC reports, including its Annual Report on
Form 10-K, and its Quarterly Reports on Form 10-Q.
